Cargando…

Cellular and Humoral Immune Responses in Type 1 Diabetic Patients Participating in a Phase III GAD-alum Intervention Trial

OBJECTIVE: GAD formulated in aluminum hydroxide (GAD-alum) has previously been shown to induce preservation of residual insulin secretion in recent-onset type 1 diabetes, but recent phase II and III GAD-alum trials failed to reach primary outcomes. The European phase III study was therefore closed a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Axelsson, Stina, Chéramy, Mikael, Åkerman, Linda, Pihl, Mikael, Ludvigsson, Johnny, Casas, Rosaura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816912/ https://www.ncbi.nlm.nih.gov/pubmed/23863909 http://dx.doi.org/10.2337/dc12-2251

Ejemplares similares

Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD(65)-induced immune response
por: Tavira, Beatriz, et al.
Publicado: (2017)

Long-Lasting Immune Responses 4 Years after GAD-Alum Treatment in Children with Type 1 Diabetes
por: Axelsson, Stina, et al.
Publicado: (2011)

Intralymphatic GAD-alum Injection Modulates B Cell Response and Induces Follicular Helper T Cells and PD-1+ CD8+ T Cells in Patients With Recent-Onset Type 1 Diabetes
por: Barcenilla, Hugo, et al.
Publicado: (2022)

Mass Cytometry Identifies Distinct Subsets of Regulatory T Cells and Natural Killer Cells Associated With High Risk for Type 1 Diabetes
por: Barcenilla, Hugo, et al.
Publicado: (2019)

Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)
por: Casas, Rosaura, et al.
Publicado: (2022)

Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes
por: Hannelius, Ulf, et al.
Publicado: (2020)

Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2
por: Nowak, Christoph, et al.
Publicado: (2022)

Latent Autoimmune Diabetes in Adults: Background, Safety and Feasibility of an Ongoing Pilot Study With Intra-Lymphatic Injections of GAD-Alum and Oral Vitamin D
por: Björklund, Anneli, et al.
Publicado: (2022)

Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes
por: Tavira, Beatriz, et al.
Publicado: (2018)

Serum miRNA levels are related to glucose homeostasis and islet autoantibodies in children with high risk for type 1 diabetes
por: Åkerman, Linda, et al.
Publicado: (2018)

Association between treatment effect on C‐peptide preservation and HbA1c in meta‐analysis of glutamic acid decarboxylase (GAD)‐alum immunotherapy in recent‐onset type 1 diabetes
por: Nowak, Christoph, et al.
Publicado: (2022)

Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol
por: Ludvigsson, Johnny, et al.
Publicado: (2022)

Engineered immunogen binding to alum adjuvant enhances humoral immunity
por: Moyer, Tyson J., et al.
Publicado: (2020)

Combined vitamin D, ibuprofen and glutamic acid decarboxylase-alum treatment in recent onset Type I diabetes: lessons from the DIABGAD randomized pilot trial
por: Ludvigsson, Johnny, et al.
Publicado: (2020)

STUDIES ON ANTIBODY PRODUCTION : III. THE ALUM GRANULOMA
por: White, Robert G., et al.
Publicado: (1955)

GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells
por: Arif, Sefina, et al.
Publicado: (2020)

Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies
por: Salami, Falastin, et al.
Publicado: (2022)

Mass Cytometry Studies of Patients With Autoimmune Endocrine Diseases Reveal Distinct Disease-Specific Alterations in Immune Cell Subsets
por: Magnusson, Louise, et al.
Publicado: (2020)

Increase of Neutrophil Extracellular Traps, Mitochondrial DNA and Nuclear DNA in Newly Diagnosed Type 1 Diabetes Children but Not in High-Risk Children
por: Skoglund, Camilla, et al.
Publicado: (2021)

Author Correction: A Engineered immunogen binding to alum adjuvant enhances humoral immunity
por: Moyer, Tyson J., et al.
Publicado: (2020)

Co‐Anchoring of Engineered Immunogen and Immunostimulatory Cytokines to Alum Promotes Enhanced‐Humoral Immunity
por: Chang, Jason Y. H., et al.
Publicado: (2022)

Alum Pastilles
Publicado: (1860)

Alum as an Emetic
Publicado: (1854)

Is Alum Poisonous?
Publicado: (1879)

Alum in Pertusis
Publicado: (1847)

Alum as an Emetic
Publicado: (1854)

Bougies with Alum
Publicado: (1845)

Physical Activity, Blood Glucose and C-Peptide in Healthy School-Children, a Longitudinal Study
por: Huus, Karina, et al.
Publicado: (2016)

How alum works
por: Bashyam, Hema
Publicado: (2008)

Alum Injection for Dysentery
Publicado: (1890)

Ammonia Iron Alum
por: Kemp,, et al.
Publicado: (1868)

Alum in Typhoid Fever
Publicado: (1888)

Alum Baking Powders
Publicado: (1914)

Iron and Alum Mass
Publicado: (1877)

Lessons From the Mixed-Meal Tolerance Test: Use of 90-minute and fasting C-peptide in pediatric diabetes
por: Besser, Rachel E.J., et al.
Publicado: (2013)

Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype
por: Puente-Marin, Sara, et al.
Publicado: (2023)

An Experimental Study of the Anti-oxidant and the Anti-inflammatory Effects of Alum and Burnt Alum
por: Seo, Hyung-Sik
Publicado: (2012)

GABA and Combined GABA with GAD65-Alum Treatment Alters Th1 Cytokine Responses of PBMCs from Children with Recent-Onset Type 1 Diabetes
por: Heath, Katie E., et al.
Publicado: (2023)

Good MRI images: to Gad or not to Gad?
por: Steen, Henning, et al.
Publicado: (2007)

Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients
por: Casas, Rosaura, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ikb5er5hm4d2be441qe8br74t7